Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 MOD GRF 1-29 / without DAC 5mg

CJC-1295 MOD GRF 1-29 / without DAC 5mg Research Handling Note: For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dis

CJC-1295 MOD GRF 1-29 / without DAC 5mg

Research Handling Note:

For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolution. *Reconstitution solutions are supplied separately.

Stock: 2818

Model: MOD CJC1295 5mg

Molecular Formula: C152H252N44O42

SKU: CJCMOD5

Research Only: Yes

Certificate of analysis

Description

Technical Data

CJC 1295 without DAC 5mg - Research Grade Peptide

CJC 1295 without DAC 5mg, also known as Modified GRF (1-29), is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). This 29 amino acid peptide, a truncated form of GHRH, plays a significant role in endocrine system research.

Product Name: CJC 1295 without DAC 5mg

Catalogue Number: CJC5

Molecular Weight: 3368.7 g/mol

Purity: 98%

CAS Number: 863288-34-0

Form: Lyophilised Solid

Scientific Research Applications:

Studies on CJC 1295 without DAC 5mg have explored its interaction with the GHRH receptor. This area of research contributes to understanding various endocrine signalling pathways.

Description and Usage:

Designed for research purposes, CJC 1295 without DAC 5mg is supplied in freeze-dried, lyophilised form, necessitating reconstitution with an appropriate solvent prior to use in experiments.

Legal and Safety Information:

CJC 1295 without DAC 5mg is marketed by UK-Peptides exclusively for research. Any inquiries regarding human consumption are prohibited, reinforcing our adherence to safety and regulatory guidelines.

Identification

Molecular Weight (g/mol)

3367.97 g/mol

Peptide Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg–NH2

Physical and Chemical Properties

Molecular Formula

C152H252N44O42

Physical Appearance

White lyophilised solid

Form

Sterile filtered white lyophilized ( freeze-dried)

Appearance

White to off-white lyophilised powder

Melting Point

Not applicable (decomposes before melting)

Analytical and Quality Control

HPLC Result

Shows min 98% Purity

Mass Spectrum

Consistent with structure

Purity %

>98%

Research Use and Safety

Caution

Research use only / Not for human or veterinary use

Intended Use

For laboratory research use only. Not for human or veterinary use.

Hazard Classification

Not classified as hazardous under GHS for research quantities

Storage, Handling and Stability

Storage Temperature, Opened

Lyophilized peptides although stable at room temperature for 3 months, should be stored desiccated below -18°C. Upon reconstitution of the peptide it should be stored at 4°C between 2-21 days and for future use below -18°C.

Storage Temperature, Unopened

-20 °C recommended for long-term storage

Shelf Life

2 years unopened under recommended conditions

Reconstitution Stability

Stable for up to 28 days at 2-8 °C in aqueous solution under sterile conditions

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosage

The dosage of CJC 1295 no DAC is usually 100 mcg per injection. Due to its short half-life, CJC 1295 is commonly administered 1-3 times per day.
02

Question drills

Open a question for its connected answer.

01What If I Left My CJC-1295 Out of the Fridge for 6 Hours?+

Discard the vial. A reconstituted peptide exposed to room temperature (20–25°C) for more than 2–3 hours has undergone enough thermal denaturation that bioactivity is compromised by at least 50%. The tertiary structure required for GHRH receptor binding denatures progressively above 8°C. The longer the exposure, the greater the loss. Visual inspection cannot detect this damage. Using a degraded vial means injecting a partially inactive compound that delivers inconsistent results and wastes the remaining protocol. Temperature-compromised peptides are not salvageable.

SOURCE / realpeptides.co ↗
02What If I Miss a Scheduled Injection by Two Days?+

Administer the missed dose as soon as you remember if fewer than three days have passed since the scheduled injection. If more than three days late, skip that dose entirely and resume your regular schedule with the next planned injection. CJC-1295's extended half-life means serum levels remain elevated for 6–8 days after administration. Missing one dose causes a dip but not a complete loss of pharmacological effect. Doubling up doses to 'catch up' pushes IGF-1 into supraphysiological territory and creates the exact metabolic disruption the twice-weekly schedule was designed to avoid.

SOURCE / realpeptides.co ↗
03What If I want to compare CJC-1295 to a GHRP — what endpoint should I measure to see the mechanistic difference?+

Measure time-integrated IGF-1 AUC (area under the curve) over 7–14 days, not peak GH levels at a single timepoint. GHRPs will show higher peak GH within the first hour, but CJC-1295 will show higher cumulative IGF-1 exposure when integrated over days. If your outcome variable depends on sustained anabolic signaling (tissue repair, lean mass accretion, hepatic protein synthesis), the AUC metric captures what single-timepoint measurements miss.

SOURCE / realpeptides.co ↗
04What If I'm Already Taking Other Peptides Like BPC-157 or TB-500?+

Stacking peptides is common in research contexts, though direct interaction studies don't exist. BPC-157 and TB-500 act through different pathways (angiogenesis, actin regulation, inflammatory modulation) than CJC-1295's GH-IGF-1 axis. The mechanisms are theoretically complementary rather than redundant. If you're considering multi-peptide protocols, staging them (e.g., BPC-157 during weeks 1–4, CJC-1295 during weeks 3–12) may reduce the number of simultaneous variables and allow clearer assessment of individual contributions.

SOURCE / realpeptides.co ↗
05What if CJC-1295 stops producing GH elevation after several weeks of use?+

CJC-1295 pharmacology studies tracked GH and IGF-1 response for up to 12 consecutive weeks and found no evidence of tachyphylaxis or receptor desensitization. If GH response diminishes, the most likely explanations are inadequate peptide storage (temperature excursions above 8°C denature the peptide), underdosing relative to body weight, or use of a degraded or impure product. Phase II data showed consistent IGF-1 elevation throughout 12 weeks at 60 mcg/kg twice weekly. The pituitary continues responding to CJC-1295 without downregulation.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

CJC-1295 for Joint Pain Research Evidence — Real Peptides

Most peptide compounds marketed for joint health don't have published human trials demonstrating direct cartilage repair. CJC-1295 is no exception. The mechanism is indirect: CJC-1295 raises endogenous growth hormone (GH) levels by extending the half-life of growth hormone-releasing hormone (GHRH), which theoretically supports collagen synthesis and tissue regeneration. But claiming it 'treats joint pain' misrepresents the current evidence base. What exists are rodent studies showing improved healing markers, scattered anecdotal reports from bodybuilding communities, and a handful of small human trials on GH elevation. None specifically targeting osteoarthritis or degenerative joint disease. Our team has reviewed hundreds of peptide research protocols across institutional labs and private research facilities. The pattern is consistent: peptides that modulate GH pathways show promise in tissue repair models, but translating those findings to human joint pathology requires controlled trials that don't yet exist for CJC-1295. How does CJC-1295 relate to joint pain research evidence? CJC-1295 is a synthetic analogue of GHRH engineered with a Drug Affinity Complex (DAC) modification that extends its plasma half-life to approximately 6–8 days, compared to minutes for native GHRH. By prolonging GHRH activity, it amplifies pulsatile growth hormone release from the anterior pituitary. Growth hormone stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which drives chondrocyte proliferation, collagen type II synthesis, and proteoglycan deposition. All components of cartilage matrix repair. The joint pain connection is extrapolated from this cascade, not from direct clinical trials measuring pain reduction or functional improvement in arthritic populations. The research gap matters. CJC-1295 appears in preclinical wound healing studies and age-related sarcopenia trials, but published data specifically addressing joint pathology. Synovial inflammation, cartilage degradation, or chronic pain scores. Remains absent. If you're evaluating using CJC-1295 for joint pain research evidence, you're working from mechanistic plausibility rather than validated clinical endpoints.

RESEARCH

Key Research Applications for CJC-1295

Alright, so we know what CJC-1295 is and how it works. But what can you actually do with it in a research setting? The potential applications are quite broad, touching on several areas of significant scientific interest. For instance, in studies focusing on Muscle Building Research, researchers investigate CJC-1295's role in promoting lean muscle mass development and enhancing recovery processes. Elevated GH levels are known to play a part in protein synthesis and tissue repair, making this a natural area of inquiry. We've seen considerable interest from institutions exploring these avenues, particularly as the demand for efficient recovery protocols grows in 2026. Beyond muscle, CJC-1295 is also a subject of intense scrutiny in Metabolic & Weight Research. Growth hormone influences fat metabolism, potentially aiding in lipolysis (fat breakdown). Studies often look at how sustained GH elevation might impact body composition, particularly in models of obesity or metabolic dysfunction. It's a complex interplay, but the initial data points towards intriguing possibilities. This is why a thorough CJC-1295 beginners guide must cover these diverse applications. Furthermore, researchers are exploring its impact on Longevity Research and general well-being. Optimized GH levels are sometimes associated with improved skin elasticity, bone density, and even cognitive function in certain populations. While the full scope of these effects is still being mapped out, the foundational research on CJC-1295 is providing crucial pieces of the puzzle. It's a field brimming with potential, and we're excited to support researchers pushing these boundaries. Our commitment to providing high-purity peptides facilitates these groundbreaking studies, allowing you to focus on the science without worrying about the integrity of your compounds. For those focused on a holistic approach, considering a Fat Loss & Metabolic Health Bundle might also be relevant for broader metabolic research.

POTENTIAL BENEFITS

What Are the Benefits of CJC 1295 Treatment in Arizona?

CJC 1295 treatment offers a plethora of benefits, making it a popular choice for those looking to optimize their health and well-being. Here are some of the key advantages:
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

Growth Hormone Pathway Mechanisms: GHRH vs Ghrelin Receptor Targeting

CJC-1295 alternatives in 2026 best divide into two mechanistic categories: GHRH receptor agonists (which mimic the body's natural growth hormone-releasing hormone) and ghrelin rec…